Vyloy: payments to doctors
Payments that named Vyloy as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.3M
- Providers
- 4,399
- Transactions
- 9,201
- Average per transaction
- $146
The per-transaction average — $146 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 4,399 providers the average total is $306, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Astellas Pharma US Inc | $1,083,417 | 80.5% |
| Astellas Pharma Global Development | $146,118 | 10.9% |
| Astellas Pharma Europe Ltd | $116,064 | 8.6% |